Literature DB >> 11576213

Immunotherapy of melanoma.

C Smith1, V Cerundolo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11576213      PMCID： PMC1783273          DOI： 10.1046/j.1365-2567.2001.01297.x

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


× No keyword cloud information.
  58 in total

1.  Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

Authors:  C Scheibenbogen; A Schmittel; U Keilholz; T Allgäuer; U Hofmann; R Max; E Thiel; D Schadendorf
Journal:  J Immunother       Date:  2000 Mar-Apr       Impact factor: 4.456

2.  Characterization of the GAGE genes that are expressed in various human cancers and in normal testis.

Authors:  O De Backer; K C Arden; M Boretti; V Vantomme; C De Smet; S Czekay; C S Viars; E De Plaen; F Brasseur; P Chomez; B Van den Eynde; T Boon; P van der Bruggen
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

3.  Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.

Authors:  E Jäger; E Stockert; Z Zidianakis; Y T Chen; J Karbach; D Jäger; M Arand; G Ritter; L J Old; A Knuth
Journal:  Int J Cancer       Date:  1999-10-22       Impact factor: 7.396

4.  Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.

Authors:  F Wang; E Bade; C Kuniyoshi; L Spears; G Jeffery; V Marty; S Groshen; J Weber
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

5.  Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides.

Authors:  E Jäger; M Maeurer; H Höhn; J Karbach; D Jäger; Z Zidianakis; A Bakhshandeh-Bath; J Orth; C Neukirch; A Necker; T E Reichert; A Knuth
Journal:  Int J Cancer       Date:  2000-05-15       Impact factor: 7.396

6.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.

Authors:  P P Lee; C Yee; P A Savage; L Fong; D Brockstedt; J S Weber; D Johnson; S Swetter; J Thompson; P D Greenberg; M Roederer; M M Davis
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

7.  MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression.

Authors:  S Lucas; E De Plaen; T Boon
Journal:  Int J Cancer       Date:  2000-07-01       Impact factor: 7.396

8.  Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.

Authors:  E Jäger; D Jäger; J Karbach; Y T Chen; G Ritter; Y Nagata; S Gnjatic; E Stockert; M Arand; L J Old; A Knuth
Journal:  J Exp Med       Date:  2000-02-21       Impact factor: 14.307

9.  High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.

Authors:  M J Pittet; D Valmori; P R Dunbar; D E Speiser; D Liénard; F Lejeune; K Fleischhauer; V Cerundolo; J C Cerottini; P Romero
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

10.  Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.

Authors:  B Thurner; I Haendle; C Röder; D Dieckmann; P Keikavoussi; H Jonuleit; A Bender; C Maczek; D Schreiner; P von den Driesch; E B Bröcker; R M Steinman; A Enk; E Kämpgen; G Schuler
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307
View more
  4 in total

Review 1.  Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.

Authors:  Michael Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

3.  TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma.

Authors:  Qian-Jin Zhang; Robyn P Seipp; Susan S Chen; Timothy Z Vitalis; Xiao-Lin Li; Kyung-Bok Choi; Andrew Jeffries; Wilfred A Jefferies
Journal:  Int J Cancer       Date:  2007-05-01       Impact factor: 7.396

Review 4.  Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship.

Authors:  Radomir M Slominski; Tadeusz Sarna; Przemysław M Płonka; Chander Raman; Anna A Brożyna; Andrzej T Slominski
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.